Du Yufeng, General Manager of Shaanxi Sheng'ao Animal Pharmaceutical Co., Ltd.

Accepted an exclusive interview with Dong Qian from the "Times Pioneer" column of CCTV's "Old Stories" channel.

In the long journey of the company's development and growth, "inheritance" not only means the handover of responsibilities, but also implies the collision of wisdom and the burst of innovation. The growth history of Shaanxi Sheng'ao Animal Pharmaceutical Co., Ltd. is a thrilling father-son "relay race". Father Du Peng, starting from scratch, steered the company forward in the turbulent waves of the veterinary drug industry, laying the foundation for the company's survival; son Du Yufeng, taking over the baton, led the company to a broader future with bold reforms and unremitting innovation. This interview tells the story of perseverance, courage, and breakthrough.

Welcome to review this episode of "Times Pioneer"

——Interview: "Passing the Torch, Painting the Blueprint of the Enterprise"

The origin of Sheng'ao Pharmaceutical can be traced back to a crucial transformation in 1999, led by Chairman Du Peng. Faced with fierce competition in the feed additive industry, he resolutely led the company into the veterinary drug field, which had a higher technical threshold, establishing the predecessor of Sheng'ao. Starting a business was difficult, and an even greater challenge came in 2004—the country's mandatory implementation of GMP certification standards. Faced with high upgrade costs and the resulting operational pressure, the company once fell into losses and shareholders withdrew. With extraordinary resilience, Chairman Du Peng started from scratch, conducted in-depth market research, studied technology, and led the team through years of arduous efforts, finally achieving profitability and laying a solid foundation for the company's subsequent development. This journey fully demonstrates the spirit of the first generation of entrepreneurs who were not afraid of difficulties, dared to take responsibility, and operated diligently.

In 2012, Du Yufeng officially took over from his father and became the general manager. He did not follow the established path, but with keen market insight, he launched a "cutting-off-the-arm" reform—focusing on the "large-volume infusion" products, which had the lowest profit but great potential at the time, and cutting off other dosage forms. This decision caused great doubts both internally and externally. The first innovation (soft bag large-volume infusion) failed due to insufficient understanding of the needs of veterinary frontline, almost exhausting the company's savings and causing a heavy blow. However, Du Yufeng did not give up. He led the team to learn from failure, taking the problems from market feedback, and worked day and night to conduct secondary equipment transformation and technological breakthroughs. Finally, he successfully launched the revolutionary "polypropylene self-standing soft bag large-volume infusion", whose seven unique advantages (such as large diameter, large capacity, self-pulling ring, lightweight and environmentally friendly, traceability, etc.) perfectly solved the pain points of veterinary clinical practice, greatly improving efficiency. Once launched, it was widely welcomed and was once hard to find in the market. This success not only saved the company but also made Sheng'ao a participant in the formulation of industry standards. Today, Du Yufeng is leading the company towards higher goals such as "humanized" R&D and innovative multi-cavity large-volume infusion, continuing to lead the industry's development direction with innovation.

From Chairman Du Peng laying the foundation in the face of difficulties, to General Manager Du Yufeng achieving technological leaps through challenges and setbacks, the journey of Sheng'ao Pharmaceutical vividly interprets the inheritance and sublimation of two generations of entrepreneurs' spirit. The father's tenacity and pragmatism are a lighthouse, illuminating the way forward; the son's courage and innovation are the sails, driving the company forward. This "relay race", full of challenges and glory, has not only propelled Sheng'ao Pharmaceutical to become a leader in the Northwest veterinary drug field, but also provides a valuable example for our understanding of the intergenerational inheritance of Chinese private enterprises and their vitality in sustainable development through innovation. In the future, under the leadership of the new generation of helmsmen, Sheng'ao Pharmaceutical will continue to paint a more magnificent blueprint for the enterprise.